Telehealth 2025

Telehealth 2025

Telehealth 2025

In December, 2019, you probably had little or an incomplete understanding about telehealth or telemedicine.

Now, it will be one of the defining technologies of the post-Coronapocalypse legacy. One question is whether it will become mainstream when the pandemic wanes.

Here's one view.

In my view, telehealth and telemedicine 2025 will probably look something like:

  1. Increased dissemination and implementation, but probably not at a global scale.

  2. Like doctors, it will be maldistributed geographically.

  3. AI and machine learning will determine the access channel for care depending on data to recommend, if not to mandate, the most appropriate care access channel to the most appropriate healthcare professional.

  4. Triage algorithms will suggest a televisit, an office visit or an emergency or urgent care visit.

  5. Pricing models for each of these access points will evolve, much like buying a ticket on an airplane.

  6. Telesickcare will increasingly morph into telehealth and teleprevention.

  7. Sickcare, fintech, medical edtech, healthcare, AI and public health and preventive medicine infrastructures and ecosystems will congeal, unlike the present scattered system of systems.

  8. Many telemedicine platforms will be unprofitable and collapse or consolidate.

  9. Medical specialties will determine which patients benefit the most and are harmed the least by telemedicine based on outcomes, access, the complexity of decision making and available manpower for starters. For the 40% of telesickcare visits that involve the upper respiratory tract, chicken soup might be much cheaper and easier.

  10. Rules, particularly reimbursement, workflow, quality of outcomes, liability issues and ROI will continue to drive or flatten the adoption curve.

  11. Reimbursement rules will create EMR-light APIs so users don't have to spend more time documenting than doctoring.

  12. The digital divide will persist and there will continue to be haves and have-nots.

Anchoring changed behavior and making it last is perhaps the most formidable challenge. Doing so will, in large part, take removing the rules, regulations and laws that interfere with the creation of ecosystems that foster business models that spur creativity, imagination and new, useful things. Public health information and education processes will have to change as well.

Even then, let's see how long the present expedited innovation lasts. The adoption curve could flatten faster than the infection curve.

Arlen Meyers, MD, MBA is the President and CEO of the Society of Physician Entrepreneurs on Twitter@ArlenMD and Facebook.

Share this article

Leave your comments

Post comment as a guest

terms and condition.
  • Mark Andrews

    Insightful !

  • Steve Perry

    Thank you to the entire healthcare community for sacrificing so much to save so many.

  • Hayley Hills

    Telehealth will be much more sophisticated in 2025

Share this article

Arlen Meyers, MD, MBA

Former Contributor

Arlen Meyers, MD, MBA is a professor emeritus of otolaryngology, dentistry, and engineering at the University of Colorado School of Medicine and the Colorado School of Public Health and President and CEO of the Society of Physician Entrepreneurs at He has created several medical device and digital health companies. His primary research centers around biomedical and health innovation and entrepreneurship and life science technology commercialization. He consults for and speaks to companies, governments, colleges and universities around the world who need his expertise and contacts in the areas of bio entrepreneurship, bioscience, healthcare, healthcare IT, medical tourism -- nationally and internationally, new product development, product design, and financing new ventures. He is a former Harvard-Macy fellow and In 2010, he completed a Fulbright at Kings Business, the commercialization office of technology transfer at Kings College in London. He recently published "Building the Case for Biotechnology." "Optical Detection of Cancer", and " The Life Science Innovation Roadmap". He is also an associate editor of the Journal of Commercial Biotechnology and Technology Transfer and Entrepreneurship and Editor-in-Chief of Medscape. In addition, He is a faculty member at the University of Colorado Denver Graduate School where he teaches Biomedical Entrepreneurship and is an iCorps participant, trainer and industry mentor. He is the Chief Medical Officer at and and Chairman of the Board at GlobalMindED at, a non-profit at risk student success network. He is honored to be named by Modern Healthcare as one of the 50 Most Influential Physician Executives of 2011 and nominated in 2012 and Best Doctors 2013.

Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics